Turn Therapeutics Inc. Operating Expenses
Turn Therapeutics Inc. (TTRX) reported Operating Expenses of $1.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Turn Therapeutics Inc. operating expenses for the quarter ending 2026-06-30 was $1.63M, a 19.14% increase year-over-year.
- Turn Therapeutics Inc. operating expenses for the quarter ending 2026-03-31 was $1.25M, a 223.68% increase year-over-year.
- Turn Therapeutics Inc. operating expenses for the quarter ending 2025-12-31 was $2.19M, a 566.83% increase year-over-year.
- Turn Therapeutics Inc. operating expenses for the quarter ending 2025-09-30 was $1.91M, a 184.34% increase year-over-year.
- Turn Therapeutics Inc. operating expenses for fiscal 2025 was $5.86M, a 226.00% increase from fiscal 2024.
- Turn Therapeutics Inc. operating expenses for fiscal 2024 was $1.80M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.63M 10-Q · filed 2026-08-12 | $2.84M 10-Q · filed 2026-08-12 | $5.07M derived: sum of 3 quarters · filed 2026-08-12 | $6.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.25M 10-Q · filed 2026-05-11 | $3.44M derived: sum of 2 quarters · filed 2026-05-11 | $5.35M derived: sum of 3 quarters · filed 2026-05-11 | $6.72M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.11M derived: sum of 2 quarters · filed 2026-03-31 | $5.47M derived: sum of 3 quarters · filed 2026-08-12 | $5.86M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.91M 10-Q · filed 2025-11-13 | $3.28M derived: sum of 2 quarters · filed 2026-08-12 | $3.67M 10-Q · filed 2025-11-13 | $3.99M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.37M 10-Q · filed 2026-08-12 | $1.75M 10-Q · filed 2026-08-12 | $2.08M derived: sum of 3 quarters · filed 2026-08-12 | $2.75M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $385.00K 10-Q · filed 2026-05-11 | $713.95K derived: sum of 2 quarters · filed 2026-05-11 | $1.39M derived: sum of 3 quarters · filed 2026-05-11 | |
| 2024-12-31 | $328.96K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.00M derived: sum of 2 quarters · filed 2026-03-31 | $1.80M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $672.99K 10-Q · filed 2025-11-13 | $1.47M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |